Naronapride (ATI-7505)
Gastroparesis
About Renexxion
Renexxion is a clinical-stage biotech company advancing naronapride (ATI-7505), a minimally absorbable, dual-mechanism (5-HT4 agonist/D2 antagonist) prokinetic drug candidate for major GI disorders with high unmet need. Its lead program is in a global Phase 2b trial for gastroparesis with partner Dr. Falk Pharma, with a Phase 2b in PPI-non-responsive GERD planned for 2026. The company is privately held, backed by a $100M investment commitment, and has built a robust IP portfolio around its compound.
View full company profileAbout Renexxion
Renexxion is a clinical-stage biotech company advancing naronapride (ATI-7505), a minimally absorbable, dual-mechanism (5-HT4 agonist/D2 antagonist) prokinetic drug candidate for major GI disorders with high unmet need. Its lead program is in a global Phase 2b trial for gastroparesis with partner Dr. Falk Pharma, with a Phase 2b in PPI-non-responsive GERD planned for 2026. The company is privately held, backed by a $100M investment commitment, and has built a robust IP portfolio around its compound.
View full company profileAbout Renexxion
Renexxion is a clinical-stage biotech company advancing naronapride (ATI-7505), a minimally absorbable, dual-mechanism (5-HT4 agonist/D2 antagonist) prokinetic drug candidate for major GI disorders with high unmet need. Its lead program is in a global Phase 2b trial for gastroparesis with partner Dr. Falk Pharma, with a Phase 2b in PPI-non-responsive GERD planned for 2026. The company is privately held, backed by a $100M investment commitment, and has built a robust IP portfolio around its compound.
View full company profileTherapeutic Areas
Other Gastroparesis Drugs
| Drug | Company | Phase |
|---|---|---|
| TAGSS Pyloroplasty | Endo-TAGSS | Pre-clinical |
| M107 | Aclipse Therapeutics | Phase 2 |
| Real-World Evidence & Post-Market Surveillance | Enterra Medical | Post-Market |
| Astressin Platform | Sentia Medical Sciences | Pre-clinical |
| NEREUS™ (tradipitant) | Vanda Pharmaceuticals | Development |
| ABP-450 | AEON Biopharma | Research |